ustekinumab
Jump to navigation
Jump to search
English
[edit]Etymology
[edit]From -kin- (“interleukin”) + -umab (“human monoclonal antibody”).
(This etymology is missing or incomplete. Please add to it, or discuss it at the Etymology scriptorium.)
Noun
[edit]ustekinumab (uncountable)
- (pharmacology) A human monoclonal antibody directed against interleukin 12 and interleukin 23, in clinical trials for multiple sclerosis, psoriasis, and psoriatic arthritis.
- 2015 December 4, “Patient Preferences for Biologicals in Psoriasis: Top Priority of Safety for Cardiovascular Patients”, in PLOS ONE[1], :
- As another interleukin 12/23 antagonist, briakinumab, was withdrawn from further development in part due to concerns about cardiovascular safety, discussion has also emerged on cardiovascular safety of ustekinumab.